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ABSTRACT
Objective: Multiple sclerosis (MS) is a chronic and progressive neurological disease affecting the central
nervous system (CNS). Some studies report an association between MS pathogenesis and cytokines. Here,
we aimed to determine and evaluate serum kisspeptin-10 level in MS patients and its related clinic pa-
rameters. Materials and Methods: A total of 92 participants, 46 patients with relapsing-remitting MS (mean
age, 38.92 ± 14.76; 22 men and 24 women) and 46 healthy controls (mean age, 37.04 ± 15.49; 22 men and
24 women) were enrolled in the study. All MS patients were neurologically examined, and magnetic
resonance imaging (MRI) was performed. Clinical data (neuropathic pain, expanded disability status scale
(EDSS) score, etc.) and the patients’ demographic characteristics were recorded. The serum level of kiss-
peptin-10 was analyzed by enzyme-linked immunosorbent assay (ELISA) method. Results: The level of
kisspeptin-10 was measured as 2.305 ± 2.781 ng/mL in MS patients and 9.342 ± 9.483 ng/mL in controls.
MS patients had significantly lower kisspeptin-10 levels than controls (P 5 0.000). Kisspeptin-10 has the
highest diagnostic value [Area under curve (AUC) 5 0.881, 95% confidence interval (CI), 0.812–0.950] as
cut-off value (2.470), sensitivity (80.40%) and specificity (72.87%) in the MS group. Furthermore, the
kisspeptin-10 level was negatively correlated with third ventricle diameter (TVD) (P 5 0.048) and vitamin
D concentration (P 5 0.004). No significant difference was determined between kisspeptin-10 and other
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clinical parameters. Conclusion: As a potential prognostic biomarker, serum kisspeptin-10 level was
significantly lower in patients with MS than in those without. Moreover, we observed negative correlations
between vitamin D, TVD size, and kisspeptin-10. We think comprehensive studies are needed to verify and
elucidate this issue.
KEYWORDS
kisspeptin-10, multiple sclerosis, neurological disease, third ventricle, vitamin D
INTRODUCTION
As a progressive neurological disease, multiple sclerosis (MS) is defined by perivenular
inflammatory lesions and demyelinating plaques within the central nervous system (CNS) [1].
Typical symptoms of MS are observed in patients between 20 and 40 years of age (about 60–
65%). MS symptoms are usually diagnosed between 15 and 50 years of age, and the prevalence of
the disease in women is about twice that in men [2, 3].
Free radicals, neurogenic inflammation, and oxidative stress have important roles in the
pathogenesis of MS [4]. Although its underlying causes still remain unclear, the disease is often
characterized by environmental factors such as Epstein-Barr virus infection, vitamin D defi-
ciency, exposure to ultraviolet B light, smoking, and obesity [5]. Based on the literature, MS is
considered to be an autoimmune disease, partially related to genetic susceptibility and envi-
ronmental factors [6]. Evidence has shown that the progression of MS is correlated with the
abnormally low or high expression of certain cytokines. A previous study indicated that the
levels of tumor necrosis factor-alpha (TNFa) were increased in the cerebrospinal fluid (CSF) of
MS patients and related to the progression and severity of the disease [7]. In the study by
Vranova et al. [8], however, it was determined that CSF and serum levels of cystatin C were
significantly lower in MS patients than in the controls. Currently, various protocols, including
McDonald criteria, CSF analyses, magnetic resonance imaging (MRI), etc. are used to diagnose
MS in clinical procedures. However, there are no effective biomarkers for the diagnosis, prog-
nosis, and evaluation of MS. The identification of sensitive and predictive biomarkers may
provide advantages in terms of early diagnosis and lower costs for clinical trials.
Kisspeptin, which is a neuropeptide of the arginine-phenylalanine (RF) amide family, is
encoded by the kiss-1 gene and involved in many physiological events such as the initiation of
puberty, the regulation of prolactin release, glucose homeostasis, and anti-metastatic and anti-
oxidative effects [9, 10]. The gene of kisspeptin (kiss-1) is located at 1q32.1 in humans and
consists of three introns and four exons [11]. The first product of this gene is kisspeptin-145
(145 amino acid protein/Kp145). After the proteolytic cleavage of the precursor protein, Kp145
generates a 54-amino acid-amidated peptide (Kp54), and then shorter degradation fragments
are formed, such as Kp14, Kp13, and Kp10 (Kisspeptin-10) [12]. All these fragments of kiss-
peptin are capable of binding to the coupled-G protein receptor (GPR54/Kiss1R) and play
significant roles in the regulation of the hypothalamic-pituitary-gonad axis, as well as the in-
hibition of proliferation, cell motility, chemotaxis, metastasis and invasion [13].
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Messenger RNAs (mRNA) of kisspeptins and kiss1R are expressed especially in the brain,
hypothalamus, spinal cord, liver, placenta, cardiovascular system and lymph nodes [14]. During
stress and inflammation, there is a decrease in kisspeptin and kiss1R expression, and also
insufficiency in kisspeptin responsiveness [15]. Kisspeptin-10, the most bioactive fragment, is
well-known as a potent anticoagulant, antitumor, angiogenic and vasoconstrictive neuropeptide
[16]. However, the data about the function and role of kisspeptin-10 in neurological diseases are
very limited.
Based on the literature, there is little or no information regarding the relationship between
MS and kisspeptin-10. This study was performed to examine whether the serum level of kiss-
peptin-10 is associated with MS, and there also is a relationship between kisspeptin-10 and
disease-related clinic parameters.
MATERIALS AND METHODS
A total of 92 participants admitted to the Neurology Department between July and October 2020
were enrolled in the study. The study was composed of 46 MS patients (mean age: 38.92 ± 14.76,
22 men and 24 women) diagnosed with relapsing-remitting MS (RRMS) in the attack-free
period through magnetic resonance imaging (MRI). MRI studies have shown focal lesions with
contrast enhancement in the arterial phase and decreased contrast in the late venous phase. The
healthy control group was composed of 46 participants (mean age: 37.04 ± 15.49, 22 men and 24
women) without any neurological disease or history of MS. Female participants in both the
patient and healthy control groups were in the pre-menopausal period (mean age: 37.00 ± 9.43
and 37.42 ± 9.13, respectively).
The exclusion criteria included subjects with the following: chronic heart failure, renal
failure, thyroid disease, mental illnesses, endocrinopathies, cardiovascular diseases, diabetes
mellitus, pregnancy, neurologic disease, and those with a history of any gynecological disorders.
The expanded disability status scale (EDSS) was performed in MS patients, and the rating in-
tensity for scores ranged from 0 (no disability) to 10 (maximum disability) [17]. The sizes of the
third ventricle diameter (TVD) and pituitary diameter (PD) of MS patients were measured by an
experienced radiologist using a 1.5-Tesla MRI scanner (Siemens, Germany). The brain MRI
protocol including axial T1-weighted turbo spin-echo (linear resolution: 0.1 mm, gap: 1.5 mm,
and slice thickness: 5 mm) was used to measure TVD. The three-dimensional (3D) spectro-
scopic imaging sequence was used to acquire the localized data focused on the hypothalamus
region through point resolved spectroscopy (PRESS) (TE/TR 5 30/1,500 ms, FOV was 10 3 10
3 8, interpolated to 16 3 16 3 8 cm3 with a nominal voxel size of 10 3 10 3 12.5 mm3 and
volumes of interest (VOIs) 50 3 60 3 35 mm3, 7 min acquisition and elliptical weighting). In
each patient, TVD was defined as the maximum transverse dimension of TVD between the
tuberal regions of the hypothalamus. T1-weighed MP-RAGE dataset was reoriented to the AC–
PC (AC 5 anterior commissure, PC 5 posterior commissure) plane. The trans-axial slice of 2
mm below the anterior commissure was selected. After denoising, up-sampling, and the seg-
mentation of MR images, TVD was defined as the maximum transverse dimension of TVD
between the tuberal regions of the hypothalamus [18]. The dimensions of PD were taken as the
maximum distance in mm between lateral and superoinferior surfaces, whereas PD was ob-
tained by multiplying the height 3 depth 3 width 3 0.52 [19]. The estimations of TVD and
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PD were expressed as mm and mm3, respectively. Body mass index (BMI) was also calculated as
weight (kg) divided by the square of the height (m). Fatigue was measured using the fatigue
severity scale (FSS) as a range scale from 1 (strongly disagree) to 7 (strongly agree) [20].
Additionally, the questionnaire of Douleur Neuropathique 4 questions (DN4) was performed to
evaluate neuropathic pain in MS patients [21]. MS patients had received no vitamin D sup-
plements and medications for at least 6 months before the investigation. Blood samples were
collected in anticoagulant-free tubes from each participant, and such features as age, sex,
medical history, and other clinical information were recorded. Also, the samples of both female
groups were taken in the non-menstrual period. After immediate centrifugation at 2.0003rpm
(at 4 8C for 20 min), serum aliquots of 1 mL were frozen immediately at 80 8C and kept until
the assay. The present study was approved by the ethics committee of Necmettin Erbakan
University Medicine Faculty, Turkey, and conformed to the ethical guidelines of the Declaration
of Helsinki in 1961 and later amendments. Written informed consent was obtained from all
participants before the enrollment.
Measurements of serum kisspeptin-10 and vitamin D levels
Serum concentrations of kisspeptin-10 were assessed by an immunoenzymatic method with the
commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the
manufacturer’s instructions (Human Kisspeptin-10 Elisa Kit, standard curve range: 0.05 ng/mL-
10 ng/mL, sensitivity: 0.02 ng/mL, intra-assay CV: 8%; interassay CV: 10%; catalog no.
E3919Hu, Bioassay Technology Laboratory, Shanghai, China). The absorbance of the samples
was measured by a microtiter plate reader at 450 nm (ELx800TM, Bio-Tech Instruments, USA),
and the levels of kisspeptin-10 were expressed in units of ng/mL. Serum levels of vitamin D were
assessed by chemiluminescence immunoassay (CLIA) method with the commercially available
Architect 25-OH vitamin D kit and measured by Abbott Architect i1000SR immunoassay
analyzer. The levels of vitamin D were also expressed in units of ng/mL.
Statistical analysis
Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS)
software package, version 22.0 (SPSS Inc, Chicago, IL, USA). The statistical significance of the
difference between the variables was tested using the Mann-Whitney U-test. Correlations were
analyzed with the Spearman rank correlation coefficient test. Receiver operating characteristic
(ROC) curves were generated by plotting the sensitivity against 1-specificity, and the cut-off
values were determined by Youden’s index method. The data were expressed as mean ±
standard deviation (SD). Statistical significance was defined as P < 0.05.
RESULTS
All the characteristics of MS patients and healthy controls are shown in Table 1. In the study, the
mean ages of 46 patients with MS and 46 healthy controls were found as 38.92 and 37.04 years,
respectively. The serum kisspeptin-10 level was significantly lower in the patients with MS than
in those without (2.305 ± 2.781 ng/mL and 9.342 ± 9.483 ng/mL, respectively; P 5 0.000). No
significant correlation was found between kisspeptin-10 levels and EDSS score, disease duration,
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Table 1. Comparison of socio-demographics, serum kisspeptin-10 level and other clinical findings between
MS patients and healthy controls
Parameters MS group (n546) Healthy group (n546) P
Age (y), mean 38.92 ± 14.76 37.04 ± 15.49 0.129
Male 40.35 ± 7.38 37.75 ± 8.66 0.442
Female 37.00 ± 9.43 37.42 ± 9.13 0.826
Sex
Male (n) 22 (47.82%) 22 (47.82%) –
Female (n) 24 (52.18%) 24 (52.18%)
Kisspeptin-10 (ng/mL)
Mean/Median 2.305 ± 2.781/1.795 9.342 ± 9.483/3.845 0.000p
Male 2.52 ± 3.97 6.42 ± 7.09 0.000p
Female 2.18 ± 1.84 11.59 ± 10.56 0.000p
BMI (kg/m2) 25.513 ± 4.081 23.437 ± 2.36 0.167
EDSS score (0–10) 1.945 ± 1.841 N/A –
Disease duration (y) 8.869 ± 6.259 N/A –





Neuropathic pain 4.043 ± 3.210 N/A –
Fatigue (1–7) 5.826 ± 2.885 N/A –
TVD (mm) 5.163 ± 1.909 N/A –
PD (mm3) 257.244 ± 18.631 N/A
Vitamin D (ng/mL) 26.154 ± 18.631 N/A –
BMI: Body mass index, EDSS: Expanded disability status scale, MS: Multiple sclerosis, NA: Not applicable,
PD: Pituitary diameter, TVD: Third ventricle diameter. Data were presented as mean ± standard deviation,
and descriptive statistics were calculated via the Mann-Whitney U test. pA P value < 0.05 was considered to
be statistically significant.
Table 2. Correlations of serum kisspeptin-10 levels with other clinical findings in MS patients including




Disease duration 0.164 0.276
Number of attacks 0.099 0.512
Neuropathic pain 0.106 0.485
Fatigue 0.058 0.753
TVD (mm) 0.293 0.048p
PD (mm3) 0.070 0.644
EDSS score 0.157 0.297
Vitamin D 0.182 0.004p
EDSS: Expanded disability status scale, MS: Multiple sclerosis, TVD: Third ventricle diameter, PD: Pituitary
diameter. pA P value < 0.05 was considered to be statistically significant.
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Table 3. Correlations of kisspeptin-10 serum levels of MS patients concerning other clinical findings in




r P r P
Disease duration 0.00 0.987 0.44 0.078
Number of attacks 0.15 0.449 0.10 0.692
Neuropathic pain 0.18 0.338 0.01 0.955
Fatigue 0.00 0.992 0.15 0.564
TVD (mm) 0.40 0.031p 0.10 0.708
PD (mm3) 0.18 0.343 0.35 0.165
EDSS score 0.08 0.697 0.65 0.007
Vitamin D 0.55 0.002p 0.37 0.142
EDSS: Expanded disability status scale, MS: Multiple sclerosis, TVD: Third ventricle diameter, PD: Pituitary
diameter. pA P value < 0.05 was considered to be statistically significant.





-10 0 10 20 30 40
Observed Value























2.470 80.40% 72.87% 80.69% 74.31%
AUC: Area under the curve, CI: Confidence interval, MS: Multiple sclerosis, NPV: Negative
predictive value, PPV: Positive predictive value 
Fig. 1. ROC curve and predictive power of the serum kisspeptin-10 concentration in MS patients and
normal-detrended plots of serum kisspeptin-10
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number of attacks, neuropathic pain, fatigue, and PD. As demonstrated in Table 2, a negative
correlation was found between kisspeptin-10 levels and [22] TVD size (r 5 0.293, P 5 0.048)
and [15] vitamin D (r 5 0.182, P5 0.004). As shown in Table 3, a negative correlation was
found between kisspeptin-10 levels in female MS patients and [22] TVD size (r 5 0.40, P 5
0.031) and [15] vitamin D (r 5 0.55, P 5 0.002). ROC curve analysis and plots of kisspeptin-
10 are shown in Fig. 1.
DISCUSSION
The pathophysiology and etiology of MS, an incompletely known, complex disease remain
elusive. As an inflammatory and demyelinating disease, the condition may lead to severe
physical and cognitive impairments due to various neurological defects in CNS [23]. The
immunopathogenesis of MS involves a process triggered by CD4þT4 cells against CNS antigens
and supported by B cells, resulting in demyelination of oligodendrocyte and loss of axons [24].
Although the pathogenesis of axonal loss and demyelination is not fully understood, the effects
of inflammatory cytokines, such as nitric oxide, interleukin-1 (IL-1) beta, TNF-alpha and matrix
metalloproteinases, and other effects produced by CD4þ and CD8þT cells, active microglia/
macrophages, and complement proteins play important roles in these processes [25].
Novel proteins and cytokines have been investigated for the diagnosis, prognosis and clinical
evaluation in MS. The redundancy or deficiency in the levels of these biomarkers may provide
valuable contributions to many diseases. Therefore recent studies have focused on revealing the
relationship between newly identified proteins and possible related diseases. In a recent study, it
has been observed that serum tau (a phosphoprotein) and decreased brain-derived neurotrophic
factor (BDNF) levels increased to a higher extent among MS patients than controls [26]. It has
also been proposed that serum levels of tau and BDNF may be used as biomarkers of the severity
of MS. In a study by Alpua et al. [22] high serum levels of apelin-13 were reported in MS
patients, compared with the controls. Another study also revealed that serum cystatin C levels of
MS patients were significantly lower than those in the controls (P 5 0.008) [27]. In our study,
serum kisspeptin-10 levels were significantly decreased in the MS group, compared to the
controls (2.305 ± 2.781 and 9.342 ± 9.483 ng/mL, respectively, P 5 0.000).
In a study, TVD diameters in MS patients and controls were determined as 3.9 ± 1.6 mm
and 3.4 ± 0.8 mm, respectively [28]. Additionally, because of determining the increased size of
TVD in MS patients (6.2 ± 1.7 mm), d’Alessandro et al [29]. proposed that the increase in third
ventricle diameter may represent a criterion of positivity of neurological disease in those with
chronic cerebrospinal venous insufficiency. Moreover, a recent study has reported that TVD
measurements below the hypothalamic sulcus may point to hypothalamic atrophy [18]. In our
study, TVD measurements were performed to determine the extent of hypothalamic atrophy,
and PD was also measured due to the neuroendocrine connection between the hypothalamus
and pituitary. As shown in Table 1, the sizes of TVD and PD were measured in MS patients
below the hypothalamic sulcus as 5.163 ± 1.909 mm and 257.244 ± 18.63 mm3, respectively.
There was also a significant correlation between TVD size and kisspeptin-10 (r 5 0.293, P 5
0.048). Even so, no significant correlation was found between PD size and kisspeptin-10 level (P
5 0.644) (Table 2). In female MS patients, a negative correlation was found between kisspeptin-
10 levels and TVD size (r 5 0.40, P 5 0.031) (Table 3).
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The overall immunomodulatory effects of vitamin D on different categories of B and T
lymphocytes and several cytokines have been well-established in recent years. In many
immunological studies conducted in MS patients, it was demonstrated that vitamin D is likely
to affect MS via various immunomodulatory mechanisms. However, vitamin D leads to many
beneficial immunological effects such as the reduction of IL-10 cytokines, pro-inflammatory
Th17 lymphocytes, the weakening of the harmful cytokine IL17, and B cell immunoreactivity.
Several studies have shown that vitamin D levels are lower in MS patients than those in the
controls. Hatamian et al [30]. reported that serum levels of vitamin D were determined to be
lower in MS patients, compared to healthy controls (26.5 ± 16.3 ng/mL and 37.1 ± 19.7 ng/
mL, respectively, P 5 0.003). In the present study, serum vitamin D levels were found as
26.154 ± 18.631 ng/mL in MS patients. Also, there was a negative correlation between vitamin
D and kisspeptin-10 (r 5 0.182, P 5 0.004) (Table 2). As shown in Table 3, a negative
correlation was found between kisspeptin-10 level and vitamin D in female MS patients (r 5
0.55, P 5 0.002).
A wide variety of MS-induced chronic symptoms may cause spasms, spasticity, fatigue,
bladder dysfunction and pain [31]. The most common type is usually burning, stinging, pain, or
central neuropathic pain defined as paroxysmal neuralgia. In clinical practice, the most
commonly used scales for the assessment of MS are visual/numerical analog scales and EDSS,
based on the subjective evaluation of the patients [32]. In our study, there was no significant
association between kisspeptin-10 level and EDSS score, neuropathic pain and fatigue in MS
patients (Table 2).
To the best of our knowledge, no data are available on circulating levels of kisspeptin-10 in
those with MS so far, and our study is the first to investigate the kisspeptin-10 level in MS
patients. Further research in the field of potential biomarkers for MS should be directed towards
an earlier and more accurate diagnosis, as well as targeted and individualized therapeutic
approach with minimal intervention and economic cost. As a result, kisspeptin-10 may be a
valuable prognostic tool in the MS disease. We consider that further comprehensive studies with
a larger sample size should be conducted to verify our findings.
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